Custirsen is designed to block production of clusterin, a cell survival protein that is over-produced in several cancer types of cancer and in response to many cancer treatments, including hormone ablation therapy, chemotherapy and radiation therapy.
You are hereHome › For Patients
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance. Our product candidates have the potential to re-define treatment paradigms in a variety of cancers.
We are currently evaluating two drugs for the treatment of prostate, lung, and bladder cancers.